

Product Information

Anti-Annexin I Antibody, Mouse Monoclonal

Clone ANEX 5E4/1, Purified from hybridoma cell culture

A3359

Product Description

Monoclonal Anti-Annexin I (mouse IgG1 isotype) is derived from the hybridoma ANEX 5E4/1 produced by the fusion of mouse myeloma cells SP2 cells and splenocytes from BALB/c mice immunized with a mixture of native membrane proteins from human bone tissues which would include whole native annexin proteins.¹ The isotype is determined using a double diffusion immunoassay using Mouse Monoclonal Antibody Isotyping Reagents, ISO2. The antibody is purified from culture supernatant of hybridoma cells grown in a bioreactor.

Monoclonal Anti-Annexin I recognizes human annexin I. The product may be used in several immunochemical techniques including ELISA, immunoblotting (~37 kDa), and immunocytochemistry.¹

Annexin, I belong to a family of Ca²⁺ dependent phospholipid binding proteins which have molecular weights of 35,000-40,000 Da and are preferentially located at the cytosolic face of the plasma membrane. Annexin I protein has phospholipase A2 inhibitory activity. Since phospholipase A2 is required for the biosynthesis of the potent mediators of inflammation, prostaglandins and leukotrienes, annexin I may have potential anti-inflammatory activity.

Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide as a preservative and also containing fetal calf serum.

Antibody concentration: ~1.5 mg/mL

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses.

Storage/Stability

Store at -20 °C. For continuous use, the product may be stored at 2-8 °C for up to one month. For extended storage, freeze at -20 °C in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

Product Profile

Immunoblotting

A working antibody dilution of 4-8 µg/mL is recommended using A431 cells extract.

Note: In order to obtain the best results using various techniques and preparations, we recommend determining optimal working dilutions by titration.

References

1. Lo, W.F., et al., J. Immunol., 162, 5398-5406 (1999).
2. Hunt, D.F., et al., Science, 255, 1261-1263 (1992).
3. Kurepa, Z., et al., J. Exp. Med., 188, 973-978 (1998).
4. O`Callaghan, C.A., Microbes Infect., 2, 371-380 (2000).
5. Russle, E., et al., J. Exp. Med., 190, 1801-1812 (1999).
6. Kraft, J.R., et al., J. Exp. Med., 192, 613-623 (2000).
7. Lo, W.F., et al., Nat. Med., 6, 215-281 (2000).
8. Sarantopoulos, S., et al., J. Clin. Invest., 114, 1218-1221 (2004).
9. Li, L., et al., J. Immunol., 173, 3707-3715 (2004).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Terms and Conditions of Sale

Warranty, use restrictions, and other conditions of sale may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

The life science business of Merck operates
as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2024 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

A3359pis Rev 11/24

